Mirodenafil belongs to the drug class PDE5 inhibitors, which includes avanafil, sildenafil, tadalafil, udenafil, and vardenafil, and is the first-line treatment for erectile dysfunction.

Developed by SK Chemicals Life Science, mirodenafil is marketed in Korea under the trade name Mvix, offered both as tablets (50 mg and 100 mg) and as orally dissolving films (50 mg).

Despite several clinical trials having been conducted,[1][2][3] mirodenafil has not been approved for use in the United States by the U.S. Food and Drug Administration.

This drug article relating to the genito-urinary system is a stub.

You can help Wikipedia by expanding it.